{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T03:29:39Z","timestamp":1762918179285,"version":"3.37.3"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2020,12,28]],"date-time":"2020-12-28T00:00:00Z","timestamp":1609113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81771745","81971517","81971525"],"award-info":[{"award-number":["81771745","81971517","81971525"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Jiangsu Provincial Medical Talent Program","award":["ZDRCA2016059"],"award-info":[{"award-number":["ZDRCA2016059"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To evaluate serum concentration and activity of angiotensin-converting enzyme 2 (ACE2) in patients with connective tissue diseases (CTDs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Serum samples from healthy subjects and patients with SLE, systemic sclerosis (SSc), primary Sj\u00f6gren\u2019s syndrome (SS) and RA were collected. The concentration and activity of ACE2 were measured by ELISA and fluorometric method, respectively, and analysed for associations with clinical features and concurrent medications.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In total, 66 SLE, 55 SSc, 31 SS and 31 RA patients were involved. ACE2 concentration was significantly decreased in patients with either of the four CTDs compared with healthy subjects. The concentration was not linked to special clinical features expect that it was slightly lower in patients with lupus nephritis than those without. In SLE patients, ACE2 concentration elevated with the increase of glucocorticoids, and was not associated with other treatments. Different from the concentration, ACE2 activity was increased in CTD patients. A weak correlation of ACE2 activity with SLE disease activity index score was also observed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The clinical significance of ACE2 concentration and activity looks quite different among CTD patients. Preliminary data suggest ACE2 levels are not affected by most of the treatments.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaa898","type":"journal-article","created":{"date-parts":[[2020,12,12]],"date-time":"2020-12-12T12:39:54Z","timestamp":1607776794000},"page":"4401-4406","source":"Crossref","is-referenced-by-count":9,"title":["Decreased serum ACE2 levels in patients with connective tissue diseases"],"prefix":"10.1093","volume":"60","author":[{"given":"Xiaojun","family":"Tang","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Immunology, Nanjing University Medical School Affiliated Drum Tower Hospital, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linyu","family":"Geng","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Nanjing University Medical School Affiliated Drum Tower Hospital, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuebing","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Nanjing University Medical School Affiliated Drum Tower Hospital, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingyun","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Nanjing University Medical School Affiliated Drum Tower Hospital, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,12,28]]},"reference":[{"key":"2021090119440160000_keaa898-B1","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/d41586-020-01824-5","article-title":"Coronavirus breakthrough: dexamethasone is first drug shown to save lives","volume":"582","author":"Ledford","year":"2020","journal-title":"Nature"},{"key":"2021090119440160000_keaa898-B2","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1056\/NEJMoa2012410","article-title":"Observational study of hydroxychloroquine in hospitalized patients with COVID-19","volume":"382","author":"Geleris","year":"2020","journal-title":"N Engl J Med"},{"key":"2021090119440160000_keaa898-B3","doi-asserted-by":"crossref","first-page":"10970","DOI":"10.1073\/pnas.2005615117","article-title":"Effective treatment of severe COVID-19 patients with tocilizumab","volume":"117","author":"Xu","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021090119440160000_keaa898-B4","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/art.41301","article-title":"American College of Rheumatology guidance for the management of rheumatic disease in adult patients during the COVID-19 pandemic: version 1","volume":"72","author":"Mikuls","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2021090119440160000_keaa898-B5","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1007\/s10067-020-05073-9","article-title":"Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets","volume":"39","author":"Misra","year":"2020","journal-title":"Clin Rheumatol"},{"key":"2021090119440160000_keaa898-B6","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1007\/s10067-020-05189-y","article-title":"COVID-19, chronic inflammatory rheumatic disease and anti-rheumatic treatments","volume":"39","author":"Ouedraogo","year":"2020","journal-title":"Clin Rheumatol"},{"key":"2021090119440160000_keaa898-B7","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2020-217615","article-title":"What is the true incidence of COVID-19 in patients with rheumatic diseases?","volume":"80","author":"Favalli","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2021090119440160000_keaa898-B8","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1002\/art.41388","article-title":"Incidence of COVID-19 in patients with rheumatic diseases treated with targeted immunosuppressive drugs: what can we learn from observational data?","volume":"72","author":"Favalli","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2021090119440160000_keaa898-B9","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.semarthrit.2020.05.001","article-title":"Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs","volume":"50","author":"Michelena","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"2021090119440160000_keaa898-B10","doi-asserted-by":"crossref","first-page":"e250","DOI":"10.1016\/S2665-9913(20)30095-3","article-title":"Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries","volume":"2","author":"Gianfrancesco","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"2021090119440160000_keaa898-B11","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1126\/science.abb2762","article-title":"Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2","volume":"367","author":"Yan","year":"2020","journal-title":"Science"},{"key":"2021090119440160000_keaa898-B12","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/path.5471","article-title":"Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19)","volume":"251","author":"Bourgonje","year":"2020","journal-title":"J Pathol"},{"key":"2021090119440160000_keaa898-B13","doi-asserted-by":"crossref","first-page":"R85","DOI":"10.1186\/ar3012","article-title":"Autoantibodies to angiotensin-converting enzyme 2 in patients with connective tissue diseases","volume":"12","author":"Takahashi","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"2021090119440160000_keaa898-B14","doi-asserted-by":"crossref","first-page":"108410","DOI":"10.1016\/j.clim.2020.108410","article-title":"Epigenetic dysregulation of ACE2 and interferon-regulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients","volume":"215","author":"Sawalha","year":"2020","journal-title":"Clin Immunol"},{"key":"2021090119440160000_keaa898-B15","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1136\/annrheumdis-2020-217888","article-title":"Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US \u2018hot spot\u2019","volume":"79","author":"D\u2019Silva","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2021090119440160000_keaa898-B16","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/annrheumdis-2020-217871","article-title":"Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry","volume":"79","author":"Gianfrancesco","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2021090119440160000_keaa898-B17","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1136\/annrheumdis-2020-217424","article-title":"Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies","volume":"79","author":"Monti","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2021090119440160000_keaa898-B18","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/s12916-020-01673-z","article-title":"New insights into genetic susceptibility of COVID-19: an ACE2 and TMPRSS2 polymorphism analysis","volume":"18","author":"Hou","year":"2020","journal-title":"BMC Med"},{"key":"2021090119440160000_keaa898-B19","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1172\/JCI97650","article-title":"iRhom2 promotes lupus nephritis through TNF-alpha and EGFR signaling","volume":"128","author":"Qing","year":"2018","journal-title":"J Clin Invest"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaa898\/35200901\/keaa898.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/9\/4401\/40215102\/keaa898.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/9\/4401\/40215102\/keaa898.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T19:45:21Z","timestamp":1630525521000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/9\/4401\/6053836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,28]]},"references-count":19,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,12,28]]},"published-print":{"date-parts":[[2021,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa898","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"type":"print","value":"1462-0324"},{"type":"electronic","value":"1462-0332"}],"subject":[],"published-other":{"date-parts":[[2021,9,1]]},"published":{"date-parts":[[2020,12,28]]}}}